- Scancell Holdings
- 25 June 2025 12:56:53
Source: Sharecast
The AIM-traded company said the first eight patients had been dosed, including participants recruited via the NHS Cancer Vaccine Launch Pad, with no significant adverse events reported.
Cohort four marks a key milestone for the iSCIB1+ programme, focusing on an alternative delivery method that Scancell said could enhance patient outcomes.
Interim data from the cohort was expected around the end of 2025, while additional results from cohorts one to three were due in July.
“The SCOPE data reported so far are highly encouraging, with SCIB1 immunotherapy showing excellent efficacy and long-term survival benefits that signal a meaningful improvement over standard of care,” said chief medical officer Dr Nermeen Varawalla.
“Initiation of cohort four is an important milestone for our iSCIB1+ programme to evaluate intradermal administration on our path towards randomised studies.”
The SCOPE trial was assessing SCIB1/iSCIB1+ in combination with checkpoint inhibitors in late-stage melanoma, with over 140 patients enrolled across four cohorts.
Data from cohort one showed an 84% disease control rate, 80% progression-free survival, a 20% complete response rate and a 72% overall response rate - all improvements over current standard treatments.
Cohort three, evaluating next-generation iSCIB1+ with ipilimumab and nivolumab, was now fully enrolled.
Chief executive Phil L’Huillier added that the continued momentum in the SCOPE study highlighted the clinical potential of SCIB1 and iSCIB1+ to address the unmet needs in melanoma.
“We are also progressing our commitment to unlock the full potential of our innovative GlyMab platform by establishing GlyMab Therapeutics,” he said.
“We are looking to bring focus to our product development execution while positioning ourselves to deliver future value through strategic optionality in a time of market headwinds.”
At 1155 BST, shares in Scancell were up 2.81% at 10.05p.
Reporting by Josh White for Sharecast.com.